Latest News from Origin
Origin increases holding in Echion
We have increased our stake in battery materials business, Echion Technologies, to just under 10%. Origin originally invested in Echion’s August 2018 seed round, reinvested in 2019, and was a significant participant in the company’s £10m Series A round, that has recently completed. See here for more information.
Origin Capital co-leads £2.1m investment in platform biotech Somaserve
Origin Capital was the largest investor in a £2.1m funding round recently completed by Somaserve, a developer of specialised nanoparticle technologies for delivery of pharmaceutical and other therapeutic agents to targeted cell types. Read more here.
CyTAL secures investment from Origin Capital
We have made a significant investment in CyTAL, a provider of cybersecurity product assurance services. The funding will support CyTAL’s accelerated growth plans for ProtoCrawler, its specialist “fuzz-testing” software application, used for identifying vulnerabilities in a wide range of connected devices. Read more here.
